Defibrotide
- TRADE NAME: Defitelio (Jazz)
- INDICATIONS: Hepatic veno-occlusive disease in patients with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation
- CLASS: Oligonucleotide
- HALF-LIFE: <2 hours
Contra-indicated for concomitant administration with systemic anticoagulant or fibrinolytic therapy.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric